Hadassah

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

Monday, Oct 24 2011

Liver Disease Early Diagnosis Device Developed at Hadassah Medical Center Receives Exemption from FDA, Providing Fast Track for Approval

BreathID, a noninvasive early diagnosis device for acute liver failure developed at the Hadassah University Medical Center, has obtained a United States Food and Drug Administration (FDA) Humanitarian Device Exemption, which provides a fast-track toward approval. Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine A is Medical Director of BreathID's developer, Exalenz Bioscience Ltd., a startup company of Hadasit, Hadassah's technology transfer arm.

The device, as well as saving lives through early diagnosis, can lead to the elimination of unnecessary liver transplants. The humanitarian use device (HUD) designation which BreathID received means that the device does not have to undergo an efficacy trial, thereby greatly shortening the approval process if it meets FDA requirements. BreathID's effectiveness in diagnosing acute liver failure was demonstrated in a trial of several dozen patients at Hadassah and London's Kings College.
The FDA has already approved a clinical trial of the BreathID device for the early diagnosis of Hepatocellular Carcinoma, a liver cancer.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Hadassah Removes Tumor;
Gazan Boy Walks for First Time

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More